Literature DB >> 7680693

Granulocyte-macrophage-colony-stimulating factor differentially regulates neutrophil migration across IL-1-activated and nonactivated human endothelium.

K L Yong1, D C Linch.   

Abstract

The directed migration of neutrophils across vascular endothelium to localize in inflammatory tissues is controlled by soluble mediators, including cytokines and growth factors. Granulocyte-macrophage CSF (GM-CSF) enhances and primes neutrophil functions, but its specific role in the movement and localization of neutrophils to infective sites has not been clarified. We demonstrate, using an in vitro model of the vascular endothelial barrier, that GM-CSF enhances neutrophil migration across unstimulated endothelium, increasing the percentage of migrating cells from 7.7 +/- 0.9% (mean +/- SE) in controls to 12.5 +/- 1.5% in the presence of GM-CSF (100 ng/ml) (n = 14, p < 0.0005). This effect is dose dependent, with maximal effects achieved at concentrations of 10 ng/ml or greater, and is independent of concentration gradients of GM-CSF. Transendothelial migration of neutrophils can also be increased by cytokine treatment of the endothelial cells. Preincubation of endothelial monolayers with IL-1 (10 U/ml) for 4 h increases the percentage of migrating cells to 16.8 +/- 1.4% (238 +/- 25% of base line, n = 7, p < 0.005). In the presence of GM-CSF, however, neutrophil migration across IL-1 treated endothelium (12.5 +/- 1.6%, n = 7) is no different from that across resting endothelium (11.6 +/- 1.6% in the same seven experiments). Hence GM-CSF acts to inhibit neutrophil migration across IL-1-activated endothelium, and almost completely abolishes IL-1-induced migration (n = 7, p < 0.0005). This differential effect of GM-CSF on neutrophil migration, depending upon the conditions of endothelial activation, does not relate to an effect on adhesion, because GM-CSF has no effect on the increased adhesion of neutrophils to IL-1-treated endothelium. The effect of GM-CSF on neutrophil migration across activated endothelium may be relevant to the clinical administration of human rGM-CSF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680693

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration.

Authors:  N J Borthwick; A N Akbar; L P MacCormac; M Lowdell; J L Craigen; I Hassan; J E Grundy; M Salmon; K L Yong
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Transendothelial migration confers a survival advantage to activated T lymphocytes: role of LFA-1/ICAM-1 interactions.

Authors:  N J Borthwick; A A Akbar; C Buckley; D Pilling; M Salmon; A P Jewell; K L Yong
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

3.  Cytokines induce selective granulocyte chemotactic responses.

Authors:  D B Bittleman; R A Erger; T B Casale
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

Review 4.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

5.  Hepatic regulation of lymphocyte adhesion to, and activation on, syngeneic endothelial monolayers.

Authors:  R M Gorczynski; Z Cohen; X M Fu; G Levy; H Plapler; B Sullivan
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

6.  Highly metastatic 13762NF rat mammary adenocarcinoma cell clones stimulate bone marrow by secretion of granulocyte-macrophage colony-stimulating factor/interleukin-3 activity.

Authors:  C T McGary; M E Miele; D R Welch
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

7.  Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis.

Authors:  Emma M Pinder; Anthony J Rostron; Thomas P Hellyer; Marie-Helene Ruchaud-Sparagano; Jonathan Scott; James G Macfarlane; Sarah Wiscombe; John D Widdrington; Alistair I Roy; Vanessa C Linnett; Simon V Baudouin; Stephen E Wright; Thomas Chadwick; Tony Fouweather; Jatinder K Juss; Edwin R Chilvers; Susan A Bowett; Jennie Parker; Daniel F McAuley; Andrew Conway Morris; A John Simpson
Journal:  Thorax       Date:  2018-07-31       Impact factor: 9.139

8.  Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.

Authors:  D E A Greven; E S Cohen; D M Gerlag; J Campbell; J Woods; N Davis; A van Nieuwenhuijze; A Lewis; S Heasmen; M McCourt; D Corkill; A Dodd; J Elvin; G Statache; I P Wicks; I K Anderson; A Nash; M A Sleeman; P P Tak
Journal:  Ann Rheum Dis       Date:  2014-06-16       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.